CAJ | 학술논문

目的：评价人工肝血浆滤过透析（PDF）模式及人工肝血浆置换（PE）+血液滤过透析（CHDF）模式在晚期肝衰竭患者中的疗效对比。方法：选取肝衰竭晚期患者40例，随机均分为观察组和对照组；观察组在内科综合治疗基础上给予 PDF 治疗，对照组在内科综合治疗基础上给予 PE + CHDF 治疗，比较两组在治疗前、后临床肝功能生化的改善情况及对临床治疗3个月病死率的影响。结果：两组治疗前生化治疗比较无差别（P ﹥0.05），两组治疗后比较，对照组较观察组改善明显（P ﹤0.05），两组3个月死亡率相同，无统计学意义。结论：晚期肝衰竭患者在内科综合治疗基础上配合 PE + CHDF 治疗与配合 PDF 治疗相比，能获得更好的肾功能改善及脱水效果，相近的肝功能指标改善明显，但在节约治疗时间及治疗成本的控制方面 PDF 更有优势。两组患者3个月病死率相同。
목적：평개인공간혈장려과투석（PDF）모식급인공간혈장치환（PE）+혈액려과투석（CHDF）모식재만기간쇠갈환자중적료효대비。방법：선취간쇠갈만기환자40례，수궤균분위관찰조화대조조；관찰조재내과종합치료기출상급여 PDF 치료，대조조재내과종합치료기출상급여 PE + CHDF 치료，비교량조재치료전、후림상간공능생화적개선정황급대림상치료3개월병사솔적영향。결과：량조치료전생화치료비교무차별（P ﹥0.05），량조치료후비교，대조조교관찰조개선명현（P ﹤0.05），량조3개월사망솔상동，무통계학의의。결론：만기간쇠갈환자재내과종합치료기출상배합 PE + CHDF 치료여배합 PDF 치료상비，능획득경호적신공능개선급탈수효과，상근적간공능지표개선명현，단재절약치료시간급치료성본적공제방면 PDF 경유우세。량조환자3개월병사솔상동。
Objective:To evaluate and compare the efficacy of the artificial liver Plasma filtration dialysis(PDF)mode and plasma exchange(PE)plus continuous hemofiltration dialysis(CHDF)mode in the treatment of the end-stage liver failure. Methods:40 patients with the end-stage liver failure were selected and randomly divided into observation group and control group;on the basis of comprehensive treatment the observation group was given PDF medical treatment where-as the control group was given PE plus CHDF therapy. The biochemical improvement of liver function and the three-month mortality before and after the treatment were observed and compared. Results:The control group had the better biochemi-cal improvement than observation group(P ﹥ 0. 05),but the two groups had the same three-month mortality. Conclusion:PE plus CHDF therapy on the basis of comprehensive treatment can get a better improvement in renal function and dehy-dration effects than PDF therapy mode,while there is no difference between the PDF therapy and PE plus CHDF therapy on liver function improvement. But the PDF therapy on the basis of comprehensive treatment can save the therapy time and treatment costs than PE plus CHDF therapy mode. There is no difference between the PDF therapy and PE plus CHDF therapy on the three-month mortality.